Due to health issues, this site is no longer maintained and will be shut down shortly. |
The holders of convertible preferred stock are entitled to receive cash dividends at an annual rate of 6% of the liquidation preference of the convertible preferred stock. Dividends will be payable in equal quarterly installments on the first day of February, May, August and November beginning February 1, 2005. If any dividends are not declared, they will accrue and be paid at such later date, if any, as determined by Xcyte’s board of directors. Dividends on the convertible preferred stock will be cumulative from the issue date. Each share of the convertible preferred stock is convertible at any time at the option of the holder into a number of shares of common stock determined by dividing the $10 liquidation preference by the conversion price of $2.35, subject to adjustment as described below. This conversion price is equivalent to a conversion rate of approximately 4.2553 shares of common stock for each share of convertible preferred stock. Unless Xcyte redeems or exchanges the convertible preferred stock, it may elect to convert some or all of the convertible preferred stock into shares of Xcyte common stock if the closing price of Xcyte common stock has exceeded 150% of the conversion price for at least 20 out of 30 consecutive trading days ending within five trading days prior to the notice of automatic conversion. This security was issued by Cyclacel Pharmaceuticals Inc, whose common stock symbol is CYCC.
$15.75 +0.35 (2.27%)
As of 03/24/2023 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.